Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

International Stem Cell (ISCO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for International Stem Cell (ISCO) over the last 17 years, with Q3 2025 value amounting to 0.71.

  • International Stem Cell's Equity Ratio rose 836.22% to 0.71 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.71, marking a year-over-year increase of 836.22%. This contributed to the annual value of 0.76 for FY2024, which is 220.07% up from last year.
  • Latest data reveals that International Stem Cell reported Equity Ratio of 0.71 as of Q3 2025, which was up 836.22% from 0.7 recorded in Q2 2025.
  • In the past 5 years, International Stem Cell's Equity Ratio ranged from a high of 0.66 in Q2 2023 and a low of 0.93 during Q4 2021
  • Over the past 5 years, International Stem Cell's median Equity Ratio value was 0.78 (recorded in 2024), while the average stood at 0.79.
  • As far as peak fluctuations go, International Stem Cell's Equity Ratio plummeted by 8877.64% in 2021, and later surged by 2585.5% in 2023.
  • International Stem Cell's Equity Ratio (Quarter) stood at 0.93 in 2021, then grew by 5.11% to 0.88 in 2022, then grew by 11.75% to 0.78 in 2023, then rose by 2.2% to 0.76 in 2024, then rose by 5.9% to 0.71 in 2025.
  • Its Equity Ratio was 0.71 in Q3 2025, compared to 0.7 in Q2 2025 and 0.73 in Q1 2025.